Gaucher Disease Treatment Market - Global Industry Analysis and Forecast 2017 - 2025


Persistence Market Research

$ 4900

The global gaucher disease treatment market has been rising on account of advancements in the field of medical diagnostics. The medical fraternity has been making key advances in the domain of genetic studies and medicinal discharge. For this reason, the symptoms, causes, and treatment lines for gaucher disease are well-known across the healthcare domain. Owing to the aforementioned factors, the global gaucher disease treatment market is projected to attract voluminous revenues in the years to come. Gaucher disease is a rare genetic disorder caused due to the deposition of glucocerebroside in human cells. This can lead to several other problems such as anaemia, fatigue and frequent skin irritation. 

  • The occurrence of gaucher disease can also lead to low platelet count, and this is also a key driver of demand within the global gaucher disease treatment market. 
  • The efforts of the global medical fraternity to aid the treatment of gaucher disease has played a vital role in the growth of the global market. 
  • There is heavy reliance of the medical fraternity on research operations that are underway. This factor has also played an underhanded role in the growth of the global gaucher disease treatment market. 

On the basis of geography, the global gaucher disease treatment market can be segmented into Latin America, North America, the Middle East and Africa, Europe, and Asia Pacific. The gaucher disease treatment market in North America is expanding alongside advancements in the field of medical research in the US and Canada. The gaucher disease treatment market in Asia Pacific could earn fresh revenues from the growing population in India.

Gaucher disease is recessive gene dominance disorder with massive clinical heterogeneity. Symptoms of the disease include painless splenomegaly, anemia, or thrombocytopenia, chronic fatigue, hepatomegaly, bone pain, and pathologic fractures. The disease also contributes to easy incidence of bruising and bleeding through the nose. Manifested in three sub-types, the disease results from the deficiency of the enzyme glucocerebrosidase. It is the most common lysosomal storage disorder and has an incidence of approximately 1 for every 50,000 live births. The most severe form of the disease is the perinatal lethal form. Gaucher disease is said to exhibit the highest manifestation in Jewish population of Eastern and Central European region, affecting 1 out of every 450 people and the number of disease carriers is 1 out of every 10 within the descent. Increasing medical advancement in research and development for rare disorders is leading to rising awareness and could eventually lead to a cure for such rare disorders.

In past, recombinant enzyme imiglucerase was used in most patients. The treatment was effective in retrograding the visceral and hematologic symptoms of Gaucher disease. However, slow responses of the skeletal disease and pulmonary involvement is comparatively resistant to the enzyme. Treatment for Gaucher disease is typically given in high dose once a week, but, in some cases, medium dose of medicine is given every week or three times in low dose quantity. Significant responses have been observed in all type of dose regimens.

The lack of drugs in last stage of development is anticipated to limit the expansion of the Gaucher disease market, although the rise in number of patient globally tend to favor the growth of Gaucher disease treatment in the market over the forecast period. Furthermore, ERT is suggested for patients with type 1 Gaucher disease exhibiting the sign and symptoms such as anemia, thrombocytopenia and bone disorder. However, sternness and progression rate of disease varies, mainly in adults, which complicates the treatment decision for the medical specialist. Enzyme replacement therapy has widely improved the quality of life for the patients. Companies involved in producing the enzyme has also gained traction in the profit margins. As a result, the major players in this industries are strictly working for the development of the latest drug therapy for the patients suffering from Gaucher disease. Since, the population suffering from Gaucher disease is comparatively less than other fatal diseases, the treatment is costlier and development is slow. Unfortunately, it has been anticipated that in spite of improvements in diagnosis and treatment, major chunk of population having Gaucher disease may not be treated over the forecast period, due to late or misdiagnosis of the Gaucher disease, which will further affect the market.

Global market for Gaucher disease treatment market is segmented on the basis of disease type, basis of Treatment, route of administration and end user:

  • Segmentation by Disease type
    • Type 1 (neuropathic forms)
    • Type 2 (perinatal lethal form)
    • Type 3 (Slow-neurologic decay form)
  • Segmentation by Medication
    • Enzyme replacement therapy (ERT)
      • Imiglucerase (Cerezyme)
      • Velaglucerase alfa (VPRIV)
      • Taliglucerase alfa (Elelyso)
      • Others
    • Substrate reduction therapy (SRT)
      • Glucosylceramide synthase inhibitors
        • Miglustat
        • Eliglustat
    • Surgical
      • Bone marrow transplant
      • Spleen Removal
  • Segmentation by End User
    • Hospitals
    • Ambulatory Surgical Centers
    • Clinical research institutes

Increased focus on formation of research consortiums on rare diseases is leading to rising disease awareness levels and increased reporting of such diseases too. Furthermore, rising affordability for access to essential healthcare services is contributing largely to disease testing and identification at early stages. Availability of symptomatic control options and validation of the same in international consortiums and federations has been leading to greater availability of symptom control options.

Barriers include lack of companies researching on cures due to profitability issues of targeted therapy. Lack of awareness among physicians also contributes largely towards no treatments or wrong treatments. Also professional counselling is one of the most effective mediums of disease management, stigmatization of patient leads to psychological issues thus leading to absence of proper treatments.

On the basis of region presence, Gaucher disease treatment market is segmented into five key regions: North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. Presently, North America dominates the global market for Gaucher disease treatment market due to high diagnose rate and large number of facilities for enzyme replacement therapy. However, growth in Middle East and African region is expected to take exponential growth in terms of CAGR over the forecast period. Rising number of people with bone disorder is expected to fuel the Gaucher disease treatment market. The U.S. Gaucher disease treatment market is expected to dominate in terms of market share with major share among all the regions.

Some of the major market players in Gaucher disease treatment market globally includes, Abbott , Aptalis Pharma , Genzyme Corporation, GlaxoSmithKline (GSK), Pfizer Inc., Shire Human Genetic Therapies, Inc., Eli Lilly and Company, Enobia Pharma Inc., Anthera Pharmaceuticals, Inc., BioMarin Pharmaceutical Inc., MedPro Rx, Zymenex A/S, Merck Serono.

MRR.BIZ has been compiled in-depth market research data in the report after exhaustive primary and secondary research. Our team of able, experienced in-house analysts has collated the information through personal interviews and study of industry databases, journals, and reputable paid sources.

The report provides the following information:

  • Tailwinds and headwinds molding the market’s trajectory
  • Market segments based on products, technology, and applications
  • Prospects of each segment
  • Overall current and possible future size of the market
  • Growth pace of the market
  • Competitive landscape and key players’ strategies

The main aim of the report is to:

  • Enable key stakeholder’s in the market bet right on it
  • Understand the opportunities and pitfalls awaiting them
  • Assess the overall growth scope in the near term
  • Strategize effectively with respect to production and distribution

MRR.BIZ is a leading provider of strategic market research. Our vast repository consists research reports, data books, company profiles, and regional market data sheets. We regularly update the data and analysis of a wide-ranging products and services around the world. As readers, you will have access to the latest information on almost 300 industries and their sub-segments. Both large Fortune 500 companies and SMEs have found those useful. This is because we customize our offerings keeping in mind the specific requirements of our clients.